XLO
NASDAQXilio Therapeutics Inc.
Price$8.45-0.05 (-0.59%)
02:15 PM06:30 PM
News · 26 weeks53+11%
2025-12-212026-06-14
Mix3090d
- SEC Filings11(37%)
- Insider10(33%)
- Other6(20%)
- Leadership3(10%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Shannon James Samuel4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Bonstein Sara4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Curran Daniel J.4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Xu Yuan4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Ross Robert W.4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Bello Akintunde Olatokumbo4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Brennan Aoife4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- SECXilio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECSEC Form EFFECT filed by Xilio Therapeutics Inc.EFFECT - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECAmendment: SEC Form S-3/A filed by Xilio Therapeutics Inc.S-3/A - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECSEC Form SCHEDULE 13G filed by Xilio Therapeutics Inc.SCHEDULE 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xilio Therapeutics Inc.SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xilio Therapeutics Inc.SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
- SECSEC Form S-3 filed by Xilio Therapeutics Inc.S-3 - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECSEC Form 10-Q filed by Xilio Therapeutics Inc.10-Q - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECXilio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
- PRXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesOn track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Achieved development milestone under AbbVie collaboration and extended cash runway into early 2028 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for
- PRXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2026, the company granted a non-qualified stock options to purchase 1,982 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.32 per share, which is equal to the closing price of the company's common stock on May 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the f
- SECSEC Form DEF 14A filed by Xilio Therapeutics Inc.DEF 14A - Xilio Therapeutics, Inc. (0001840233) (Filer)
- PRXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models Consistent with Xilio's clinically-validated masking technology, XTX601 was well tolerated in non-human primates with a favorable therapeutic index WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced new preclinical data for XTX601, a masked T cell engager targeting claudin 18.2 (CLDN18.2), at the American Association for Cancer Research (AACR) Annual Meeting, taking place from A
- INSIDERSEC Form 4 filed by Blanchard Cheryl R4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 3 filed by new insider Blanchard Cheryl R3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- SECXilio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
- PRXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsWALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. "Cheryl brings over three decades of leadership experience advancing the development of innovative products across biologics, small molecules and medical devices, and I am pleased to welcome her to the board," said Sara Bonstein, chair of the board of direct
- PRXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2026, the company granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.48 per share, which is equal to the closing price of the company's common stock on April 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on
XLO FAQ
7 questionsWhat does Xilio Therapeutics Inc. do?
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in...Where does XLO stock trade?
Xilio Therapeutics Inc. (XLO) is listed on NASDAQ.What sector and industry is XLO in?
Xilio Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Xilio Therapeutics Inc. go public?
Xilio Therapeutics Inc. (XLO) completed its IPO in 2021.What are analysts saying about XLO?
Xilio Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $200.00 price target on 2025-08-06.What companies are similar to XLO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare XLO side-by-side with any of them on Quantisnow.How can I track XLO on Quantisnow?
Quantisnow aggregates Xilio Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XLO to receive live email and push alerts on every new disclosure.